CNBX Pharmaceuticals Inc.

CNBX PHARMACEUTICALS, INC. is a clinical stage company based in Bethesda, Maryland, focused on the discovery, development, and commercialization of cannabinoid-based products and technologies for cancer treatment. The company's lead product candidate is Cannabics SR, an oral capsule designed for patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Another key anti-neoplastic drug candidate under development is RCC-33, intended for Colorectal Cancer (CRC). The company's R&D activities are conducted in a government-licensed lab facility in Israel, concentrating on developing cannabinoid-based therapies, medications, and administration routes for cancer. CNBX PHARMACEUTICALS, INC. was incorporated on September 15, 2004, in Nevada, initially as Thrust Energy Corp., engaged in oil and gas exploration. On September 30, 2010, the company increased its authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and completed a 20-for-1 reverse split, reducing issued and outstanding common stock from 13,604,000 shares to 680,202 shares and 5,000,000 preferred shares. In April 2011, due to a lack of meaningful revenue from oil and gas exploration, the company shifted its business plan to include toll milling and refining, changing its name to American Mining Corp. on May 5, 2011. The company transitioned into a bio-tech company in 2014, with shareholders electing a new Board of Directors and renaming it Cannabics Pharmaceuticals Inc. on April 29, 2014.